Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “PLASMACYTOMA”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,243 records · Page 69Linked to original sources
PubMed1995

Primary extramedullary plasmacytoma of the liver. A case report.

We report the first case of primary extramedullary plasmacytoma of the liver. The tumor was situated in segment VIII of the liver without extrahepatic extension. Histologically, the tumor was composed of sheets of mature plasma cells with slight atypia in association with proplasmacytes invading the hepatic parenchyma. Neither plasmoblasts nor lymphoplasmacytes were present. Immunohistochemistry demonstrated monoclonal IgG and kappa light-chain expression. In situ hybridization confirmed the monotypic expression of kappa light-chain mRNA. Bone marrow examination revealed no abnormality. After surgery, the IgG kappa spike detected in preoperative plasma samples decreased. The patient is disease free 31 months postoperatively.

Aged↗
PubMed1995

Differences between Burkitt's lymphomas and mouse plasmacytomas in the immunoglobulin heavy chain/c-myc recombinations that occur in their chromosomal translocations.

Burkitt's lymphomas (BLs) and mouse plasmacytomas (MPs) are characterized by chromosomal translocations juxtaposing the c-myc oncogene to one of the immunoglobulin loci. Here we describe illegitimate recombinations and the DNA sequence at the junction between c-myc and immunoglobulin heavy chain (IgH) regions in these B-cell lineage tumors. In 15 BLs and in 29 MPs, recombination products were amplified by PCR and sequenced. Molecular analysis of the IgH/c-myc junctions revealed the following characteristics: (a) rearrangements in BLs represent nearly reciprocal exchanges between c-myc and IgH switch sequences, whereas in MPs, several hundred bp of c-myc may be duplicated or deleted; (b) short homologies of up to 5 bp between immunoglobulin and c-myc sequences can be found at most junction sites in both tumors; and (c) pentameric sequences typically found in switch regions and V(D)J recognition motifs also occur frequently at the sites of recombination in c-myc.

Animals↗
PubMed1995

Extramedullary plasmacytoma of the head and neck: use of paraffin sections to assess clonality with in situ hybridization, growth fraction, and the presence of Epstein-Barr virus.

The diagnosis of extramedullary plasmacytomas (EMP) is usually easy to conform with immunohistochemical stains for kappa and lambda. In some cases, however, immunostains are problematic. In addition, prognostic features are not well described nor is it known whether EMP are associated with the Epstein-Barr virus. Therefore, 23 EMP of the head and neck (from 20 patients) were studied to (1) compare a non-isotopic paraffin section in situ hybridization technique for kappa and lambda mRNA with standard immunohistochemical techniques for assessing light chain expression, (2) compare the histologic grade to the proliferative fraction using an antibody for the proliferating cell nuclear antigen, and (3) determine the frequency of Epstein-Barr virus (EBV) association using probes for the EBV DNA (EBV NOT 1) and RNA (EBER-1). Light chain class restriction was demonstrated in 22/23 biopsies by in situ hybridization and in 21/23 biopsies by standard immunohistochemical techniques. Five of the six biopsies of well-differentiated EMP had proliferating cell nuclear antigen scores of 0 to 10% positive cells and one had 11 to 25% positive cells compared with greater than 75% in the one poorly differentiated EMP. Of 15 moderately differentiated EMP, 10 had proliferating cell nuclear antigen scores of 11 to 75%, and 5 had scores of greater than 75%. EBV DNA was detected in 1/23 biopsies and EBV RNA in 4/23 biopsies (3 patients). Thus, non-isotopic in situ hybridization is a useful technique to document clonality of plasma cells in routinely fixed, paraffin-embedded sections. Unlike routine immunohistochemistry, in situ hybridization avoids the problem of detecting stromal or nonspecific uptake of immunoglobulin.(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗
PubMed1995

[A case of extramedullary plasmacytoma of the lung associated with nodular deposit of amyloid].

A 63-year-old man underwent left upper lobectomy because of a 35-mm tumor in the lingula. Microscopic findings showed that the tumor was composed of a proliferation of plasma cells, and that in some areas eosinophilic amorphous material had been deposited between the tumor cells. By immunoperoxidase staining, the tumor cells were positive for IgG and kappa chain, but they were negative for lambda chain. In addition to the tumor in the lingula, another nodule was found in the left lower lobe and was resected at thoracotomy. The nodule was composed of diffuse eosinophilic amorphous material, which was found to be amyloid after Congo red staining and observation in polarized light. In and around the nodule, a few plasma cells were noted and these cells were also positive for IgG and kappa chain, but negative for lambda chain immunoperoxidase staining. In serum taken from the patient before surgery, M-protein was not detected by immuno electrophoresis but polyclonal hypergammaglobulinemia was noted, and it continued after the thoractomy. Bone marrow examination and a bone scintigram revealed no abnormality. In this case, a pulmonary plasmacytma co-existed with nodular pulmonary amyloidosis. We could not determine which lesion developed first, but the results of the immunoperoxidase staining of plasma cells in both lesions indicate that the origin of the plasmacytoma was probably the same as that of the nodular amyloid.

Amyloidosis↗
PubMed1994

Extramedullary plasmacytoma of the head and neck.

Extramedullary plasmacytoma (EMP) is an uncommon malignant plasma cell neoplasm which usually presents as soft tissue mass in the head and neck. We retrospectively reviewed 7 cases with EMP of the head and neck between 1978 and 1992. All patients were male. Their ages ranged from 27 to 66 years. M-protein was identified in 5 patients (IgG-kappa in 3, IgG-lambda in 1 and Lambda light chain in 1). All but one were treated with local irradiation. Three patients received chemotherapy. All patients have been alive for 37+ to 116+ months since the diagnosis of EMP. One patient had a cervical node recurrence 9 years after local irradiation and the other one who refused local irradiation but received chemotherapy developed multiple myeloma 5 years later. Based on our experience and the review of the literature, it is recommended that irradiation to the primary sites and the involved cervical nodes is the treatment of choice. Additional chemotherapy may be considered in patients with disease progression, recurrence, or dissemination. The M-protein is a useful parameter to assess tumor control or disease progression.

Adult↗
PubMed1995

Nonrandom chromosomal change (trisomy 11) in murine plasmacytomas induced by an ABL-MYC retrovirus.

Trisomy of chromosome 11 (Ts11) is the second most frequent nonrandom chromosomal change in murine plasmacytomas (PCTs). The frequency of Ts11 is significantly higher in PCTs induced in pristane-conditioned mice infected by Abelson-murine leukemia virus (52%) compared to those induced by pristane alone (8.1%). Although the significance of Ts11 in mouse plasmacytomagenesis is not clearly understood it is hypothesized that a gene or genes located on chromosome (Chr) 11 may specifically promote the development of PCTs in which both oncogenes, c-myc and v-abl, are abundantly expressed. To test this assumption we induced PCTs by three highly effective plasmacytomagenic retroviruses: ABL-MYC, J3V1, and RIM. Nearly 90% of PCTs that arose in BALB/c, (BALB/c x DBA/2N)F1, BALB/c-nu/nu, and 5-month-old SCID mice infected with ABL-MYC virus were trisomic for Chr 11. In contrast, < 10% of PCTs induced by J3V1 or RIM retroviral constructs encompassing either v-myc and v-raf or c-myc and v-Ha-ras oncogenes, respectively, contained Ts11. We have also investigated whether the entire Chr 11 or any particular subregion is preferentially duplicated in the process of ABL-MYC plasmacytomagenesis. By inducing PCTs in F1 heterozygous mice that are carriers of reciprocal translocations involving Chr 11 we found that the duplicated chromosomal region is located distal to the T4Dn breakpoint (11B5 band) on the telomeric segment of Chr 11. The regular duplication of this chromosomal segment strongly suggests the presence of a gene or genes whose amplification is of critical importance for v-abl associated murine plasmacytomagenesis.

Animals↗
PubMed1994

Successful purging of murine plasmacytoma by mafosfamide (ASTA-Z).

Mafosfamide (ASTA-Z) is a chemotherapeutic agent currently in use for in vitro purging of tumor-bearing human BM cells prior to autologous bone marrow transplantation (ABMT). We tested the efficacy of ASTA-Z against mouse plasmacytoma cells MOPC-315 (MOPC), a model of human multiple myeloma. BALB/c mice were injected intraperitoneally with different doses of MOPC preincubated with ASTA-Z. All control mice receiving > or = 10(4) MOPC intraperitoneally (ip) died within 23 days. All recipients of ASTA-Z pretreated MOPC remained healthy for > 180 days. To simulate the clinical situation, BALB/c mice received lethal doses of 10(3) MOPC ip prior to ABMT. Subsequently, mice were treated with cyclophosphamide 200 mg/kg one day prior to syngeneic BMT with 10(7) BMC containing 10(6) MOPC; 90% of the mice receiving unpurged syngeneic BMC died within 45 days whereas all mice transplanted with ASTA-Z-treated BMC/MOPC mixtures remained disease-free for > 100 days. Our results suggest that a similar approach may be successful in patients with multiple myeloma and residual disease prior to cryopreservation of their BM for ABMT. Bone marrow purging with ASTA-Z is effective and under certain conditions could be critical for prevention of relapse following ABMT, provided that effective elimination of residual disease in the host can be achieved by the conditioning regimen prior to ABMT.

Animals↗
PubMed1975

Follow-up of certain immunologic indicators in the treatment of plasmacytoma with cyclophosphamide in combination with plasmapheresis.

Changes in the immunoglobulin and complement levels in untreated plasmacytoma were compared with those resulting from massive doses of Cyclophosphamide (15--25 mg per kg b. w. at intervals of 10--14 days) applied in combination with double plasmapheresis (involving removal of about 500 ml of plasma). A follow-up of the levels of normal immunoglobulins, paraprotein, total complement and the C3 component revealed a significant decline in the total complement following each single application of this treatment, but the decrease in C3 was nonsignificant. A decline of about 20% in immunoglobulins and of about 15% in paraprotein was observed in relation to the pretreatment values, but only that in the IgM class proved to be of statistical significance. The decrease in proteins was also established with the methods of total protein determination (refractometric or biuret methods) and was found to amount to 1000--3000 mg% after each dose of Cyclophosphamide with plasmapheresis. In the author's view, a combined Cyclophosphamide-plasmapheresis treatment is effective for achieving clinical remission. It should, however, be kept in mind that the effect of protein and paraprotein depression persists for only a few days, hence, to achieve long-term results, this treatment should be repeated in 2--3 week's cycles. The lowered values of humoral immunity indicators do not increase the danger of complications from a clinical aspect, when suitable preventive measures are taken.

Antibody Formation↗
PubMed1993

[The effect of arachidonic acid and hydrocortisone on the intracellular Ca2+ concentration in murine plasmacytoma JW cells].

Arachidonic acid (1-3 microM) induces a rapid dose-dependent rise of free Ca2+ contents [Ca2+]i in the cytoplasm of JW cells. An increase of [Ca2+]i is the consequence of Ca2+ influx and Ca2+ efflux from intracellular calcium sources. Hydrocortisone (0.5-5 microM) blocks plasma membrane Ca2+ channels and inhibits arachidonic acid-stimulated Ca(2+) influx in JW cells. The presented data suggest that arachidonic acid and hydrocortisone have membranotropic activity on plasmacytoma JW cells.

Animals↗
PubMed1993

Solitary extramedullary plasmacytoma of the oropharynx: a rare location.

We describe a case of solitary extramedullary plasmacytoma of the oropharynx growing on the left posterior tonsillar pillar. The clinical picture was difficulty in swallowing caused from the partial obstruction of the area and bleeding from the ulcerated tumor. Lambda light chains were identified on immunohistochemical staining but they were not detected in either serum or urine (non-secreting tumor). Excisional biopsy followed by radiation therapy were used for treatment. Long-term follow up for several years is necessary in order to rule out evolution to multiple myeloma.

Aged↗
PubMed1994

Identification of two genes on chromosome 4 that determine resistance to plasmacytoma induction in mice.

BALB/cAn mice are highly susceptible to the induction of plasmacytomas (PCTs) by the i.p. injection of paraffin oils, whereas DBA/2 mice are solidly resistant. To search for genes that control the dominant resistant phenotype of DBA/2, BALB/c.DBA/2 (C.D2) congenic strains were constructed, and the susceptibility and resistance to PCT development were determined. PCT formation takes place over an extended period of 365 days but begins morphologically in focal proliferations of atypical plasma cells (foci) in the reactive oil granuloma that forms on mesenteric surfaces. Cells from some of these foci spread to other locations in oil granuloma tissue, forming new foci. Mice that develop six or more foci appear to be progressing towards eventual overgrowth and replacement of all peritoneal tissues with PCT cells. From Days 100 to 250, between 28 and 56% of PCT-susceptible BALB/cAn mice had 6 or more foci, whereas less than 5% of resistant DBA/2, BALB/c x DBA/2 F1 (hereafter called CD2F1), C57BL/6, and BALB/cJ mice had 6 or more foci. Four CD2 congenic strains carrying D2 alleles of genes on chromosomes other than chromosome 4 were highly susceptible. Between 0 and 20% of the mice in C.D2-Chr 4 congenic strains C.D2-MIA, C.D2-TF3, C.D2-Fv-1n/n, C.D2-Pnd7, C.D2-Lgm-1A, C.D2-Lgm-1B, C.D2-Lgm-1C, and C.D2-Lgm-1H developed 6 or more foci from 125 to 260 days, indicating resistance. The segments of DBA/2 chromosome 4 chromatin in C.D2-Fv-1n/n and C.D2-Pnd7 were discontinuous with those in C.D2-TF3, C.D2-Lgm-1A, C.D2-Lgm-1B, C.D2-Lgm-1C, and C.D2-Lgm-1H, indicating there are at least two genes (Pctr1 and Pctr2) in the distal half of this chromosome that confer resistance. Pctr1 is located between Ifa and D4Rck41, and Pctr2 is between Tnfr-1 and Pkcz. Each locus acting alone distinctly conferred a partial resistant phenotype. Pctr1 and Pctr2 did not appear to prevent the formation of clonal foci but did appear to limit the ability of the plasma cells in foci to acquire greater autonomy; thus, these genes affect tumor progression.

Animals↗
PubMed1977

Single cutaneous plasmacytoma with crystalloid inclusions.

A patient had a primary cutaneous plasmacytoma of the cheek. Histologic studies showed dense aggregates of plasma cells admixed with occasional histiocytes. The cytoplasm of the histiocytes contained needle-like structures. Electron microscopy showed these structures to be completely enclosed within smooth membranes. They often were rhombic, with occasional broken-off corners. It is hypothesized that these structures represent protein that has been secreted by the plasma cells and subsequently phagocytosed and stored in crystalloid form by the neighboring histiocytes. The patient is asymptomatic 1 1/2 years after removal of the tumor.

Cheek↗
PubMed1994

Solitary intracranial plasmacytoma of the skull base.

Two cases of extradural solitary plasmacytoma (SIP) with infiltration of the dura, destruction of the skull base, multiple cranial nerve palsies and proptosis are presented. The cases were treated aggressively with surgery and radiotherapy and showed no signs of progressing to multiple myeloma after 15 months and four and a half years respectively.

Adult↗
PubMed1996

Extramedullary nasal plasmacytoma--an unusual clinical entity.

A case of extramedullary plasmacytoma with its unusual appearance is reported. This is the second reported case in world literature affecting the paranasal sinuses with intracranial extension. The role of surgery is to obtain tissue for diagnosis and to excise residual disease. Radiotherapy is the treatment of choice and long-term follow-up is necessary for monitoring disease recurrence. The overall 10-year survival is about 50%. The case is discussed with a general review of the management of this pathology.

Humans↗
PubMed1996

Extramedullary plasmacytoma of anorectum: case report.

A young anxious looking male presented with a referral diagnosis of recurred bilateral ischiorectal abscesses. Clinical examination and investigations showed an advanced lesion of the anorectum. Histology revealed an extramedullary plasmacytoma of the anorectum to which the patient succumbed and died within two weeks of presentation.

Adult↗
PubMed1995

Parietal bone non-secreting solitary myeloma (plasmacytoma) with spread to the epidural space and scalp. Case report.

A case of solitary osteolytic lesion in the parietal bone in an otherwise asymptomatic patient is reported. Skull radiographs showed a radio-lucent lesion with well-defined margins without sclerotic reaction, CT scan demonstrated a mass that markedly enhanced extending from the epidural to the subcutaneous space of the parietal region. The patient underwent surgery and tumor was completely excised. Pathological examination showed tumor to be a plasmacytoma synthesizing kappa chains. Postoperatively the patient received radiotherapy. Four years after treatment there was no sign of local recurrence on CT can and of progression of multiple myeloma on clinical and laboratory studies. Our recommended treatment is that of a complete surgical excision followed by radiation to dose levels of 45-50 Gy. The patients should be followed carefully because of either local recurrence or possible progression to multiple myeloma. Radiotherapy and chemotherapy should started when signs of progression or other significant disease manifestations occur.

Aged↗
PubMed1977

Solitary cerebral falx plasmacytoma.

An unusual lesion, a solitary plasmacytoma of the falx cerebri is reported. Surgical treatment and subsequent radiotherapy have been effective therapeutic modalities with no signs of recurrence or disseminated disease after two and a half years.

Adult↗
PubMed1997

TPA induces apoptosis in MPC-11 mouse plasmacytoma cells grown in serum-free medium.

Apoptotic-like events could be rapidly induced by the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA) in cells of the mouse plasmacytoma cell line MPC-11 grown in serum-free medium. Indicators for apoptosis were morphological changes visualized by light and electron microscopy, such as chromatin condensation and the formation of cellular buds and fragments, as well as biochemical indices like the appearance of the so-called 'DNA ladder'. Additionally, in these cells which are usually devoid of significant amounts of cytoplasmic intermediate filament (cIF) proteins, synthesis and accumulation of the cIF protein vimentin was rapidly induced by TPA treatment and almost all cells became vimentin-positive. Later on, substantial amounts of vimentin and lamin B degradation products appeared, and an increasing fraction of cells displayed low or even undetectable quantities of intact vimentin. This subpopulation was characterized via microscopy to be in the late stages of apoptosis. We suggest that in MPC-11 cells undergoing apoptosis in response to TPA treatment vimentin as well as lamin B are degraded, leading to a rearrangement and eventual loss of their respective filament networks.

Animals↗